Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
Clinical Colorectal Cancer
|
April 12, 2015
A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer
Khanh Do, Liang Cao, Zhigang Kang, et al.
Clinical Pharmacology and Therapeutics
|
February 15, 2023
The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial Data
Qi Liu, Raina Mathur, Yuan Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or Fusions
Janice Kim, Diana Bradford, Erin Larkins, et al.
Clinical Pharmacology and Therapeutics
|
January 23, 2026
Emulating Comparative Oncology Trials With Real-World Evidence Studies (ENCORE): Process Development and Methodological Considerations for Oncology Real-World Data
Janick Weberpals, Sebastian Schneeweiss, Kenneth L Kehl, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 13, 2016
Clinician Perspectives on Current Issues in Lung Cancer Drug Development
Saiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors
Elizabeth S Duke, Diana Bradford, Michelle Marcovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery
Michael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions
Diana Bradford, Erin Larkins, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
Clinical Colorectal Cancer
|
April 12, 2015
A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer
Khanh Do, Liang Cao, Zhigang Kang, et al.
Clinical Pharmacology and Therapeutics
|
February 15, 2023
The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial Data
Qi Liu, Raina Mathur, Yuan Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 28, 2021
FDA Approval Summary: Pralsetinib for the Treatment of Lung and Thyroid Cancers With <i>RET</i> Gene Mutations or Fusions
Janice Kim, Diana Bradford, Erin Larkins, et al.
Clinical Pharmacology and Therapeutics
|
January 23, 2026
Emulating Comparative Oncology Trials With Real-World Evidence Studies (ENCORE): Process Development and Methodological Considerations for Oncology Real-World Data
Janick Weberpals, Sebastian Schneeweiss, Kenneth L Kehl, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 13, 2016
Clinician Perspectives on Current Issues in Lung Cancer Drug Development
Saiama N Waqar, Philip D Bonomi, Ramaswamy Govindan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 2, 2023
FDA Approval Summary: Selpercatinib for the Treatment of Advanced RET Fusion-Positive Solid Tumors
Elizabeth S Duke, Diana Bradford, Michelle Marcovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery
Michael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 26, 2020
FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with <i>RET</i> Gene Mutations or Fusions
Diana Bradford, Erin Larkins, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 1, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC
Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 4, 2021
FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations
Luckson N Mathieu, Erin Larkins, Oladimeji Akinboro, et al.
Page
of 3